Exit

Harvard's genomic editing technology spinout has filed to raise up to $100m, adding to some $225m of venture funding in under three years.

Phytelligence has lost its legal case with Washington State University, leaving the board with no option but to close its crop cultivation business.

Aprea Therapeutics, a Karolinska Institute spinout, is set to raise as much as $92m from an offering that would bank Karolinska Development a return of up to $8m.

Woodford’s stake in IP Group is being sold at a 13% discount on market trading as its suspended Equity Income fund sharply pivots to FTSE 100 investments.

Allied Minds will collect $65.6m for its 58% stake in data analytics satellite operator HawkEye 360, which it founded on the back of Virginia Tech research.

Frequency Therapeutics, a regenerative medicine developer advancing MIT and Harvard research, has set the range for an initial public offering that will raise $107m if it floats at the high end.

ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.

Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.